ERBB2 and breast carcinoma: Trastuzumab, a monoclonal antibody against HER2, induces normalization and regression of the vasculature in HER2-overexpressing human breast cancer xenografts by lowering the amount of expressed proangiogenic molecules while up-regulating thrombospondin-1, which has anti-angiogenic activity (Izumi et al., 2002; Figure 2).